Torrent Suite Dx Software versions 5.14 and earlier used in connection with Ion PGM DX Systems-IV...
FDA Device Recall #Z-1426-2024 — Class II — February 7, 2024
Recall Summary
| Recall Number | Z-1426-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 7, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Life Technologies Corporation |
| Location | Frederick, MD |
| Product Type | Devices |
| Quantity | 28 units |
Product Description
Torrent Suite Dx Software versions 5.14 and earlier used in connection with Ion PGM DX Systems-IVD intended for targeted sequencing of human genomic DNA (gDNA) from peripheral whole-blood samples and DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) samples. The Ion PGM Dx Instrument System is not intended for whole genome or de novo sequencing Product Name Installer /SKU /Updater SKU: (1) Torrent Suite Dx Software 5.14 -A52422/ A52417 (2) Torrent Suite Dx Software 5.12.5- A46166/ A46167 (3)Torrent Suite Dx Software 5.8- A36601/ A36602 (4)Torrent Suite Dx Software 5.6.4- A33178/ A33178 (5)Torrent Suite Dx Software 5.0- A29166/ A29166
Reason for Recall
Torrent Suite Dx Software versions 5.14 and earlier used in connection with Ion PGM DX Systems exploitation of the vulnerability by a threat actor may allow them to alter settings, configurations, software, or data on the instrument
Distribution Pattern
US Nationwide distribution in the states of CA, IN, NC OR, TN.
Lot / Code Information
UDI: 10190302017848;10190302016810 Torrent Suite Dx Software versions 5.14 and earlier
Other Recalls from Life Technologies Corporation
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2979-2020 | Class II | The TaqPath RT-PCR COVID-19 Kit with Applied Bi... | Aug 6, 2020 |
| Z-2978-2020 | Class II | The TaqPath RT-PCR COVID-19 Kit with Applied Bi... | Aug 6, 2020 |
| Z-1706-2020 | Class II | Oncomine Dx Target Test RNA/DNA Panel- IVD for ... | Mar 16, 2020 |
| Z-1707-2020 | Class II | Ion Torrent Dx No Template Control Kit- IVD for... | Mar 16, 2020 |
| Z-1705-2020 | Class II | Oncomine Dx Target Test RNA Control- IVD for de... | Mar 16, 2020 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.